Last updated: May 2, 2026
Scope and Claims Review: WO2016071767 (WIPO)
WO2016071767 is a PCT publication in the WIPO database. The requested analysis requires the full published text of the application (claims, description, and prosecution-related documents where available) to map claim scope and build a defensible patent landscape across jurisdictions. No claim text or bibliographic record content was provided in the prompt, and the analysis cannot be completed without the actual WO publication content.
What is the claim scope of WO2016071767?
Not deliverable with the provided input. Claim scope analysis must reference the published independent and dependent claims verbatim (or with precise paraphrase tied to claim terms), including: composition vs method vs use claims; structural limitations; functional limitations; definitions; claim dependencies; and any fallback claim sets. Without the WO document text, any scope summary would be speculative and not a valid patent-claim analysis.
What does the patent landscape look like around WO2016071767?
Not deliverable with the provided input. A landscape requires: (1) the exact applicant/assignee, (2) the drug substance/compound identity or therapeutic target, (3) the priority dates and claim types, and (4) jurisdictional family members to test novelty/inventive step and estimate freedom-to-operate. Without access to the WO bibliographic data and claims, the landscape cannot be constructed to a business-useful standard.
Which claim elements need to be mapped for FTO and validity?
Not deliverable with the provided input. For a drug patent, the core claim elements to map include:
- Active ingredient definition: chemical structure, salts, polymorphs, solvates, hydrates, stereochemistry, and specific ranges.
- Therapeutic method hooks: dosing regimen, patient population, biomarkers, routes of administration, lines of therapy, and treatment endpoints.
- Use claims vs method claims: whether protection targets “use for” a therapeutic indication or a stepwise method.
- Functional limitations: activity thresholds (IC50/EC50), selectivity, pharmacokinetics, stability, bioavailability, and manufacturing properties.
- Composition breadth: excipients, carriers, formulation parameters, and stability constraints.
- Priority-based fallback: how dependent claims narrow to support enablement and inventive step.
Without the claim set, none of these elements can be mapped to actual claim language.
What competitor and generic risks typically attach to a WO like this?
Not deliverable with the provided input. Risk assessment depends on what the claims actually cover (compound, formulation, method, or use). Generic entry risk differs materially if the claims are directed to:
- a specific molecule or salt (classic compound protection),
- a formulation with defined excipients or process constraints,
- a polymorph or specific solid state form,
- a dosing regimen or combination therapy,
- or a biomarker-defined patient subgroup.
No such mapping can be done without the WO publication content.
Actionable next steps for claim capture and landscape build (document-driven)
Not deliverable with the provided input. This section would normally include a repeatable pipeline: extract independent/dependent claims, normalize claim terminology into a claim-chart schema, identify family members and key jurisdictions, then run novelty and obviousness screens against identified prior art and product labels. The prompt provides none of the WO content necessary to anchor that process.
Key Takeaways
- A complete and accurate scope and claims analysis of WO2016071767 is not possible from the information provided.
- A patent landscape cannot be constructed without the WO publication’s bibliographic record and claim text (or the publication itself).
- No defensible FTO/validity mapping can be produced without the specific independent and dependent claim language.
FAQs
-
What document content is required to analyze WO claim scope precisely?
The published claim set (independent and dependent claims) plus the definitions and claim construction cues in the description.
-
Can I infer claim scope from a WO number alone?
No. WO numbers do not encode claim language or inventive concept details.
-
How do you build a drug patent landscape from a WO?
By using the WO bibliographic record (assignee, priorities, IPC/CPC), extracting claim scope, then identifying family members and screening prior art and commercial labels in target jurisdictions.
-
What drives freedom-to-operate risk for drug WO patents?
Whether the claims cover the active ingredient vs formulation vs dosing/use, and how broadly the claim limitations read on generic and biosimilar or reformulation products.
-
Does a WO publication automatically determine enforceable scope?
No. Enforceable scope depends on granted claims in each national phase and claim construction under the relevant jurisdiction.
References (APA)
[1] World Intellectual Property Organization (WIPO). (n.d.). WO2016071767. WIPO Patentscope.
